8-K: Adverum Announces Positive Data for Ixo-vec Gene Therapy in Wet AMD, Phase 3 Trial Planned

Adverum Biotechnologies reports positive 52-week results from its LUNA Phase 2 trial and four-year follow-up data from the OPTIC extension trial for Ixo-vec in wet AMD, showcasing significant treatment burden reduction and sustained visual outcomes.

Summary

• Adverum Biotechnologies has released positive data from its LUNA Phase 2 clinical trial and the OPTIC extension trial for its gene therapy, Ixo-vec, in patients with wet age-related macular degeneration (AMD).
• The LUNA trial, involving 60 patients, showed that both doses of Ixo-vec maintained visual acuity and reduced the need for anti-VEGF injections, with an 88% and 92% reduction in mean annualized injections for the 6E10 and 2E11 doses, respectively.
• In the LUNA trial, 54% of patients on the 6E10 dose and 69% on the 2E11 dose were injection-free at 52 weeks.
• The OPTIC extension trial, with 23 patients, demonstrated an 86% reduction in annualized anti-VEGF injections over four years, with nearly 50% of patients remaining injection-free.
• The company plans to initiate the ARTEMIS Phase 3 trial in the first half of 2025, which will compare Ixo-vec to aflibercept, with a primary endpoint of non-inferiority in visual acuity at weeks 52 and 56.
• Adverum estimates the global market for wet AMD to be approximately $9 billion in 2025 and $13 billion by 2035.
• As of September 30, 2024, the company had $153.2 million in cash, expecting to fund operations into the second half of 2025.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results, strong patient preference, and a clear path to Phase 3 trials, indicating a high potential for success. However, the limited cash runway and inherent risks in drug development temper the overall sentiment slightly.

Positives

• Ixo-vec shows a potential best-in-class product profile with high injection-free rates and significant treatment burden reduction.
• The safety profile of Ixo-vec is favorable, with local steroids effectively managing inflammation.
• Patient preference for Ixo-vec is strong, indicating a potential for high adoption rates.
• The company has a clear plan for Phase 3 trials and a defined market opportunity.
• The 6E10 dose has demonstrated a strong safety profile with no inflammation at week 52 or any subsequent visit in the LUNA trial.
• Long-term data from the OPTIC trial shows sustained benefit for up to four years.

Negatives

• The company's cash runway only extends into the second half of 2025, which does not include completion of the ARTEMIS Phase 3 trial.
• Some patients experienced mild to moderate anterior inflammation, though this was managed with local corticosteroids.
• There were a few discontinuations in both trials due to adverse events unrelated to the study drug.

Risks

• The company's novel technology makes it difficult to predict the timing of clinical trials.
• There are regulatory uncertainties and risks associated with the approval process.
• Enrollment uncertainties could impact the timeline of the Phase 3 trials.
• The results of early clinical trials may not always be predictive of future clinical trials.
• There is a potential for future complications or side effects with Ixo-vec.
• Market conditions could impact the success of the product.

Future Outlook

The company anticipates initiating the ARTEMIS Phase 3 trial in the first half of 2025 and believes Ixo-vec has the potential to be a transformative, best-in-class therapy for wet AMD, shifting the treatment paradigm and establishing gene therapy as a standard of care.

Management Comments

• Management believes Ixo-vec has a potential best-in-class product profile.
• Management is confident in the safety and efficacy of the 6E10 dose for the Phase 3 program.
• Management highlights the strong patient preference for Ixo-vec over current treatments.

Industry Context

This announcement is significant as it presents a potential gene therapy alternative to frequent anti-VEGF injections, addressing a major unmet need in the treatment of wet AMD. The data suggests Ixo-vec could offer a more durable and convenient treatment option, potentially disrupting the current market dominated by frequent injection therapies.

Comparison to Industry Standards

• The reported 88-92% reduction in anti-VEGF injections in the LUNA trial and 86% in the OPTIC trial are significantly higher than what is typically seen with current standard treatments like aflibercept or ranibizumab, which require frequent injections.
• The injection-free rates of over 50% in LUNA and nearly 50% in OPTIC are also notable, as current treatments rarely achieve such high rates of injection freedom.
• Comparatively, other gene therapies in development for wet AMD, such as those from Regenxbio (RGX-314) and 4D Molecular Therapeutics (4D-150), have shown lower injection burden reductions and injection-free rates in their respective trials.
• For example, RGX-314 suprachoroidal delivery has shown lower injection-free rates and treatment burden reduction compared to Ixo-vec.
• The patient preference data, with over 90% of patients preferring Ixo-vec, is also a strong indicator of its potential market success, as patient acceptance is a key factor in the adoption of new therapies.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data and potential market opportunity.
• Patients with wet AMD may benefit from a more convenient and effective treatment option.
• Physicians may be interested in adopting a therapy that reduces the need for frequent injections.
• Payers may see the potential for cost savings due to reduced treatment burden and office visits.

Next Steps

• The company plans to initiate the ARTEMIS Phase 3 clinical trial in the first half of 2025.
• The company will continue to monitor long-term data from the OPTIC extension trial.
• The company will work towards regulatory approval for Ixo-vec.

Key Dates

Keywords

Ixo-vec, wet AMD, gene therapy, clinical trial, anti-VEGF, aflibercept, treatment burden, injection-free, macular degeneration, ARTEMIS, LUNA, OPTIC